Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lineage Cell Therapeutics Inc (NY: LCTX ) 0.9053 -0.0147 (-1.60%) Official Closing Price Updated: 8:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lineage Cell Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 May 04, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session April 13, 2023 U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga 3 Penny Stocks to Buy During Market Downturns April 10, 2023 If you're looking for penny stocks to buy that can weather economic turmoil, these should make the cut due to their strong fundamentals. Via InvestorPlace Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 09, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Preview: Lineage Cell Therapeutics's Earnings March 08, 2023 Via Benzinga RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration April 26, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 March 02, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage to Present at 2023 AAPS National Biotechnology Conference April 18, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology February 22, 2023 Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc for beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell... Via Benzinga 2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies January 25, 2023 BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. Via Benzinga Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium March 30, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks January 06, 2023 Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. Via Investor's Business Daily RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit March 20, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics's Return On Capital Employed Overview March 14, 2023 Via Benzinga RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. March 06, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications February 22, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss February 08, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Earnings Preview: Lineage Cell Therapeutics November 09, 2022 Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022 November 03, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference November 29, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 November 02, 2022 Upgrades Via Benzinga Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration November 28, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field October 14, 2022 Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. Via TheNewswire.com Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer October 31, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field October 14, 2022 By David Willey, Benzinga Via News Direct A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field October 13, 2022 Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. Via Benzinga 121 Stocks That Hit Their 52-Week Low October 14, 2022 New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. Via Benzinga Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells October 10, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa October 04, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.